Merck KGaA
$290.6K 101 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Intra-Sana Laboratories
Intra-Sana Laboratories reported $291,330.70 across General Payments, Research, and Ownership to 3,142 physicians and teaching hospitals across 3,142 transactions.
- $291.3K
- All-tracks total
- 3,142
- Transactions
- 3,142
- Recipients
- +$129.1K
- General Payments vs PY2023
Intra-Sana Laboratories reported $291,330.70 across all CMS Open Payments tracks (General + Research + Ownership) to 3,142 physicians and teaching hospitals in Program Year 2024 - ranking #899 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $291,330.70, averaging $92.72 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer intra-sana-laboratories Intra-Sana Laboratories
$291.3K · #899/1,925 · 0.0% industry · PY2024
- TOT $291.3K
- RANK #899
- SHARE 0.0%
- TXN 3,142
- RCP 3,142
- CAT 3
- GEN $291.3K
- ΔGEN +$129.1K
- TOP1 8.4%
- PY 2024
Volume peers
Nearest volume peer: Merck KGaA ($290.6K)
Intra-Sana Laboratories sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Intra-Sana Laboratories's CMS-reported General Payments increased by $129.1K (+79.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: INTRA-SANA LABORATORIESPY2023: INTRA-SANA LABORATORIESPY2024: Intra-Sana Laboratories. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $162,211.23
- PY2024
- $291,330.70
What the Data Shows for Intra-Sana Laboratories
Averaging $92.72 per transaction and $92.72 per recipient, Intra-Sana Laboratories's Program Year 2024 total comes to $291,330.70 across 3,142 transactions and 3,142 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #899 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
"Honoraria" leads the 3-category general-payment breakdown below at $172.5K (59.2% of General Payments, 101 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Honoraria" leads Intra-Sana Laboratories's 3-category general-payment breakdown at $172.5K, 59.2% of the reported total.
How Intra-Sana Laboratories divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $172.5K | 101 | 59.2% |
| Food and Beverage | $113.9K | 3,020 | 39.1% |
| Travel and Lodging | $5.0K | 21 | 1.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $106,937.28 (36.7%) of $291,330.70 in this company's General Payments records across 1,281 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Intra-Sana Laboratories
The five named recipients with the highest reported General Payments from this company
- 1
Loic S Tchokouani
$24,469.96 across 26 reported transactions
- 2
Brian Berberian
$24,052.12 across 23 reported transactions
- 3
Robert Busch
$20,862.73 across 17 reported transactions
- 4
Jason Roy
$19,226.74 across 20 reported transactions
- 5
Philip Rabito
$18,325.73 across 24 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Intra-Sana Laboratories's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Intra-Sana Laboratories.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Intra-Sana Laboratories.
Showing 6 of 1,924 companies with CMS-reported payment data.
Exo Imaging, Inc.
$292.7K 175 recipients
Compare payment profiles
Evoke Pharma, Inc.
$292.8K 3,417 recipients
Compare payment profiles
Nexxt Spine LLC
$292.8K 358 recipients
Compare payment profiles
Septodont Inc.
$289.4K 1,604 recipients
Compare payment profiles
Verity Pharmaceuticals Inc.
$293.4K 4,640 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.